“When we bring new technology to the market, we always try to be better, faster and more cost-effective than existing technologies and that means we have the patient in focus.“
Dr. Wolfgang Pusch, President Bruker Microbiology & Diagnostics
Our continuous R&D activities on MALDI Biotyper® have dramatically increased the speed of microorganism identification by the introduction of the powerful MBT Compass HT IVD* software, boosting the analysis speed of the MALDI Biotyper® sirius systems to up to 600 samples/hour.
As every year, the MALDI Biotyper® Reference Libraries have been updated by an impressive number of new species and genera, once more broadening the identification performance.
The MBT IVD Library* version 2022 has been expanded with 28 new genera and 393 new species, now covering a total number of 4,194 species, complemented by
The MBT Compass Library** (RUO) version 2022 has likewise been expanded with 28 new genera and 393 new species, now covering a total number of 4,274 species, complemented by
The coming soon MBT Mycobacteria IVD Kit shall facilitate sample preparation for Mycobacterium spp. cultivated in liquid cultures as well as on solid media. Unlike other procedures requiring boiling, the safe inactivation method holds a convenient and user-friendly incubation of the bacteria with an Inactivation Reagent. Additionally, the overall hands-on time is reduced from more than 1 hour to less than 45 minutes, yielding excellent mass spectra for sensitive and reliable mycobacteria identification by the IVD MALDI Biotyper®.
The outstanding wide mass range resolution achieved by the benchtop MALDI Biotyper® allows powerful post-processing activities by the MBT HT Subtyping IVD Module*, revealing information hidden in the spectra. The MBT HT Subtyping IVD Module* looks for decisive peaks in the identified mass spectrum or triggers a sophisticated additional algorithm, for the detection of specific resistance markers or for reliable differentiation of highly related species.
The current applications of this continuously expanding module comprise:
The low consumable cost per sample, ease of use and fast time-to-result of the IVD MALDI Biotyper® has led to more and more samples being selected for routine microbial identification. Consequently, automated sample preparation for MALDI-TOF analysis has become very desirable for improving the microbiology workflow, reducing not only manual labor, also the likelihood of human errors in sample misplacement and/or possible cross-contamination. The coming soon MBT Pathfinder® IVD provides preselection of colonies powered by AI, colony transfer and complete MALDI target preparation, all fully documented and traceable. When combined with the Feeder IVD, petri dishes are automatically fed into the tray of the MBT Pathfinder® IVD, freeing up valuable technician work time.
The latest IR Biotyper®*** software allows for seamless integration with the MALDI Biotyper® software, and conjoint feeding of data into the LIMS.
A major step forward for strain typing is the availability of predefined strain or serotype classification, based on artificial neural network (ANN). The most recent IR Biotyper® software provides classifiers for serogrouping/ serotyping of Legionella, Listeria, Streptococcus and Salmonella. In addition, customers can build their own classifiers according to their needs. Powerful visualization tools such as 3D scatter plots are supporting the fast interpretation of large data sets by unsupervised tools such as PCA (Principal Component Analysis) or supervised tools such as LDA (Linear Discriminant Analysis).
Multiple initiatives are ongoing to fight against the global antimicrobial resistance (AMR) challenge, and getting accurate AST results is critical for antibiotic stewardship teams to preserve the long-term efficacy of antibiotics. UMIC®* is Bruker´s brand for high accuracy single drug MIC testing, based on the broth microdilution reference method. These ready-to-use single strips are a perfect complement to the routine AST workflow of a clinical microbiology laboratory. The flexible solution provides EUCAST and CLSI compliance, simplicity and convenient logistics, helping to make the right decision regarding patient treatment escalation or de-escalation in the context of AMR. The current UMIC® portfolio comprises five antibiotics and antibiotic combinations: colistin, piperacillin-tazobactam, vancomycin/teicoplanin, daptomycin and linezolid.
From a drug development perspective, cefiderocol is one of the most promising antibiotics, remaining active even when facing the most challenging carbapenem resistance mechanisms. To support antibiotic stewardship, clinical microbiologists are looking for reliable and accurate cefiderocol MIC testing in full compliance with EUCAST and CLSI standards. Bruker´s coming soon UMIC® Cefiderocol and the associated iron-depleted Mueller Hinton broth offer an easy to implement solution and can conveniently be tested along with UMIC® Colistin to deliver trusted MIC results when it matters most.
Our fully validated and integrated SARS-CoV-2 workflow* offers a complete solution from patient sample to data analysis. Automated extraction is performed with the GenoXtract® fleXT*, which generates ready-to-use PCR plates for the FluoroCycler® XT* with minimal hands-on time. The FluoroCycler® XT* allows processing of up to 96 samples, has five detection channels for multiplex PCR testing and provides a fully automated analysis. The FluoroSoftware® XT-IVD* generates results at a glance, in an easy to use, easy to interpret test report. The workflow has been designed for rapid laboratory set-up and high-throughput testing.
FluoroType® SARS-CoV-2 plus (IVD)*
FluoroType® SARS-CoV-2/Flu /RSV (IVD)*
FluoroType® SARS-CoV-2 varID Q (IVD)*
FluoroType® SARS-CoV-2 evo (RUO)**
Launched at the onset of the pandemic to determine SARS-CoV-2 presence
Simultaneous detection of SARS-CoV-2, influenzas A and B, and respiratory syncytial virus (RSV)
Identification of SARS-CoV-2 mutations as well as quantification of the viral load
Detection of SARS-CoV-2 and simultaneous differentiation of four different S-gene mutations
We are diversifying our offering and are pleased to announce two new LiquidArray® powered assays as Coming Soon. These are:
The pioneering LiquidArray® technology provides next generation multiplexing capabilities.
The LiquidArray® Gastrointestinal assay (Coming Soon) detects up to 26 pathogens from stool samples in a two-well format supporting the throughput needs of the routine laboratory. The test allows detection of bacteria, viruses, parasites, and pathogen associated toxins in a single protocol.
The FluoroType® STI assay (Coming Soon) detects nine different targets, covering seven pathogens, in a single well. For Neisseria gonorrhoeae and Chlamydia trachomatis, dual target detection is provided. The accurate diagnosis of N. gonorrhoeae presents a particular diagnostic challenge. This is due to high recombination rates between different Neisseria species, and non-pathogenic Neisseria species colonizing the pharynx. FluoroType® STI provides confidence in N. gonorrhoeae reporting by requiring the detection of two independent genes to return a N. gonorrhoeae positive result.
We have further expanded our comprehensive tuberculosis and nontuberculous mycobacteria PCR diagnostics portfolio; the portfolio is unique as it includes the only leprosy molecular diagnostic test focusing on resistance in the market. Other highlights include that the portfolio enables M. tuberculosis complex detection, which is also possible in combination with first line resistance identification (with the WHO endorsed FluoroType® MTBDR VER 2.0* assay) and differentiation of nontuberculous mycobacteria.
The latest addition to the portfolio is the FluoroType® Mycobacteria VER 1.0*. The new assay is a semi-automated qualitative in vitro test for the detection and differentiation of 32 clinically relevant nontuberculous mycobacteria and the detection of M. tuberculosis complex from cultured material in one well. The assay is also powered by our unique LiquidArray® technology. Extraction is performed with our FluoroLyse extraction kit followed by analysis by FluoroCycler® XT.
We are pleased to highlight our pioneering LiquidArray® technology with the launch of the FluoroType® Mycobacteria VER 1.0 and the Coming Soon announcements for the LiquidArray® Gastrointestinal* and FluoroType® STI*. These novel assays strengthen our LiquidArray® powered multiplexing range, commencing in 2019 with the launch of the FluoroType® MTBDR VER 2.0, which detects up to 45 different resistance mediating mutations in the tuberculosis complex.
Please contact your local representative for availability of these new products.
* Please contact your local representative for availability in your country. Not for sale in the USA.
** For Research Use Only. Not for use in clinical diagnostic procedures.
*** Not for use in clinical diagnostic procedures.